Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Pediatr Blood Cancer. 2012 Feb 7;59(4):753–755. doi: 10.1002/pbc.23391

Table II.

Summary of Arsenic Trioxide in Vivo Activity Against Ewing Sarcoma Xenografts

Xenograft Line Median Time to Event P-value EFS T/C Median RTV at End of Study Tumor Volume T/C Median Group Response T/C Volume Activity EFS Activity
SK-NEP-1 8.2 0.400 1.3 >4 0.76 PD1 Low Low
EW5 10.7 0.926 1.5 >4 0.88 PD2 Low Low
EW8 10.3 0.119 0.9 >4 1.19 PD1 Low Low
TC-71 6.2 0.952 1.0 >4 0.97 PD1 Low Low
CHLA258 17.2 0.452 1.0 >4 0.88 PD1 Low Low